/

RCUS

Arcus Biosciences, Inc.Pre-market

24.34−0.07 −0.29%USD

NYSE · as of Oct 12, 16:00 ET · 20m delay

Open

24.42

Prev close

24.41

Day range

24.1224.73

52-week range

15.3831.74

Volume

1.34M0.99×

Mkt cap

3.06B

P/E ttm

—

Fwd P/E

-7.45

EPS ttm

-3.92

Div yield

0.00%

Earnings

Aug 5, 2026

From 52w high

−23.30%

Price Chart

Yahoo Finance · delayed

RCUSOct 12, 2026O 24.42H 24.73L 24.12C 24.34−0.07 (−0.29%)Vol 1.34M

SMA 5027.39
SMA 20024.83

1Y change +66.71% since Oct 10, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

RCUS Arcus Biosciences, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −1.62%
1 month: −1.02%
3 months: −13.29%
6 months: +8.71%
Year to date: +2.14%
1 year: +66.71%

Valuation & ownership

Market cap: 3.06B
Enterprise value: 2.64B
P/E (ttm): —
Forward P/E: -7.45
PEG ratio: —
Price / book: 6.66
Price / sales (ttm): 26.17
EV / EBITDA: -5.54
EPS (ttm): -3.92
EPS (forward): -3.27
Beta (5y monthly): 0.94
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 125.77M
Float: 90.53M
Short % of float: 16.81%
Short ratio (days): 7.66
Held by insiders: 28.80%
Held by institutions: 74.92%
Avg volume (3m): 1.35M
50-day average: 27.39
200-day average: 24.83
52-week change: +66.71%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): 40.1
vs 50-day SMA: −11.14%
vs 200-day SMA: −1.98%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▲ above
ATR (14) % of price: 4.85%
Realised vol (20d, ann.): 38.1%
From 52-week high: −23.30%
From 52-week low: +61.30%

ANR

Analyst Consensus

11 analysts

Consensus

Strong buy

1.31 on a 1 (strong buy) – 5 (sell) scale

Mean target

39.91

+63.97% implied

Low 23.00Median 43.00High 47.00

Recommendation trend

Now11 / 2 / 0
1m ago11 / 2 / 0

DES

About Arcus Biosciences, Inc.

Yahoo Finance profile

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Sector: Healthcare
Industry: Biotechnology
Employees: 601
Headquarters: Hayward, CA, United States
Website: arcusbio.com
Officers: Dr. Terry J. Rosen Ph.D. Co-Founder, Chairman & CEO

SEAS

Seasonality · RCUS

2018–2026 · monthly returns

Strongest month Nov +17.75%Weakest month Mar −9.64%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-11.7	-3.2	6.0	18.1	-0.6	21.7	-8.6	3.9	-11.8	-5.8			+2.1%
2025	-13.4	-15.6	-27.9	11.5	2.1	-8.8	12.2	16.0	28.4	45.0	32.4	-8.7	+60.0%
2024	-20.7	26.4	-1.3	-19.3	-1.1	1.1	7.7	4.3	-10.7	0.1	0.9	-3.6	−22.0%
2023	4.6	-15.8	0.2	-2.1	15.1	-1.1	-2.0	3.0	-12.4	-12.5	-4.1	26.8	−7.6%
2022	-23.9	20.8	-15.2	-23.3	-21.7	33.7	4.9	-9.4	8.6	-2.6	38.0	-41.2	−48.9%
2021	33.8	1.5	-20.4	20.2	-26.5	10.6	14.4	-7.1	19.5	-4.1	31.0	-7.6	+55.9%
2020	-13.1	73.3	-8.8	90.3	18.7	-21.1	-20.5	20.9	-28.0	27.2	24.9	-4.7	+157.0%
2019	-5.6	15.9	5.9	-22.2	-12.8	-6.2	-0.5	-1.3	16.5	-13.7	5.4	22.1	−6.2%
2018				-1.4	4.7	-23.2	-4.4	23.1	-3.2	-27.9	13.6	-5.7	−30.2%

INSD

Insider Activity · RCUS

Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

81.9K shares

Sells, 6 months

113.2K shares

Net shares

−31.3K

Net change in insider shares

−0.10%

Date	Insider	Transaction	Shares	Value
Aug 20, 2026	Azoy AlexanderOfficer	Sale at price 30.00 per share.	2.8K	$84.81K
Aug 20, 2026	Azoy AlexanderOfficer	Conversion of Exercise of derivative security at price 15.44 per share.	2.8K	$43.65K
Jul 9, 2026	Jaen Juan CarlosPresident	Sale at price 28.61 - 30.05 per share.	68.6K	$2.03M
Jun 23, 2026	Jaen Juan CarlosPresident	Sale at price 27.03 - 29.66 per share.	31.4K	$877.50K
Jun 10, 2026	Tang Carolyn C.General Counsel	Conversion of Exercise of derivative security at price 2.57 per share.	34.1K	$87.75K
Jun 10, 2026	Perlman Andrew JDirector	Stock Award(Grant) at price 0.00 per share.	5.7K	—
Jun 10, 2026	Falberg Kathryn E.Director	Stock Award(Grant) at price 0.00 per share.	5.7K	—
Jun 10, 2026	Kaneko YasunoriDirector	Stock Award(Grant) at price 0.00 per share.	5.7K	—
Jun 10, 2026	Machado PatrickDirector	Stock Award(Grant) at price 0.00 per share.	5.7K	—
Jun 10, 2026	Lacey David LDirector	Stock Award(Grant) at price 0.00 per share.	5.7K	—
Jun 10, 2026	Lambert NicoleDirector	Stock Award(Grant) at price 0.00 per share.	5.7K	—
Jun 10, 2026	Ribas AntoniDirector	Stock Award(Grant) at price 0.00 per share.	5.7K	—
May 31, 2026	Azoy AlexanderOfficer	Sale at price 25.77 per share.	2.6K	$66.02K
May 10, 2026	Goeltz Robert C. IiChief Financial Officer	Sale at price 25.63 per share.	7.8K	$198.97K
Jan 22, 2026	Rosen Terry JayChief Executive Officer	Stock Award(Grant) at price 0.00 per share.	79K	—
Jan 22, 2026	Jaen Juan CarlosPresident	Stock Award(Grant) at price 0.00 per share.	31K	—
Jan 22, 2026	Goeltz Robert C. IiChief Financial Officer	Stock Award(Grant) at price 0.00 per share.	24K	—
Jan 22, 2026	Jarrett A JenniferChief Operating Officer	Stock Award(Grant) at price 0.00 per share.	31K	—
Jan 22, 2026	Azoy AlexanderOfficer	Stock Award(Grant) at price 0.00 per share.	21.1K	—
Jan 22, 2026	Tang Carolyn C.General Counsel	Stock Award(Grant) at price 0.00 per share.	24K	—

RCUS

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

RCUS

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Arcus Biosciences, Inc.

Seasonality · RCUS

Insider Activity · RCUS

Congress Trades · RCUS

Congress Trades · RCUS

Insider Activity · RCUS

Seasonality · RCUS

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Arcus Biosciences, Inc.

Financial Snapshot

Earnings & Dividends

News